Solo Brands, Inc. Announces Third Quarter 2025 Results Consolidated Third Quarter 2025 Highlights Compared to Third Quarter 2024 Segment Third Quarter 2025 Highlights Compared to Third Quarter 2024 (2) Solo Stove Chubbies Solo Brands Accelerates Structural Cost Reduction to Match Current Demand Levels; Delivers $11 Million of Operating Cash in Q3, Marking Second Consecutive Quarter of Positive Cash Flow Grapevine, Texas, November 6, 2025: Solo Brands, Inc. (NYSE: SBDS) ("Solo Brands" or "the Company") a lea ...

Exhibit 99.1 News Release Edgewise Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights Sevasemten is an orally administered first-in-class fast skeletal myosin inhibitor designed to protect against contraction-induced muscle damage in muscular dystrophies including Becker and Duchenne. MESA open-label extension trial in adults with Becker: The Company continues to advance MESA, an open-label extension trial that collects long term safety and efficacy data of sevasemten t ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________________ to _________________ Commission File Number: 001-41837 Mural Oncology plc (Exact Name of Registrant as Specified in its Charter) (State or ...

Press Release Novavax Reports Third Quarter 2025 Financial Results and Operational Highlights GAITHERSBURG, Md., November 6, 2025 – Novavax, Inc. (Nasdaq: NVAX) today announced its financial results and operational highlights for the third quarter ended September 30, 2025. "We have continued the steady transformation of Novavax and are proud of our progress this quarter." said John C. Jacobs, President and Chief Executive Officer, Novavax. "This year we have relaunched the Company with a focus on R&D and pa ...

Exhibit 99.1 LSI INDUSTRIES REPORTS FISCAL 2026 FIRST QUARTER RESULTS AND DECLARES QUARTERLY CASH DIVIDEND CINCINNATI, November 6, 2025 – LSI Industries Inc. (Nasdaq: LYTS, "LSI" or the "Company") a leading U.S. based manufacturer of commercial lighting and display solutions, today reported financial results for the fiscal 2026 first quarter ended September 30, 2025. The Company declared a regular cash dividend of $0.05 per share payable on November 25, 2025, to shareholders of record on November 17, 2025. ...

Exhibit 99.1 UroGen Reports Third Quarter 2025 Financial Results as ZUSDURI™ Launch Gains Momentum PRINCETON, N.J. November 6, 2025-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced financial results for the third quarter ended September 30, 2025, and provided an overview of recent developments. "Our launch of ZUSDURI, the first and only FDA-approved medicine for adults with rec ...

Financial Performance - Net income for Q3 2025 was $16.3 million, or $0.96 per diluted common share, up from $11.2 million, or $0.66 per diluted common share in Q3 2024, representing a 45.5% increase in net income year-over-year [113]. - For the nine months ended September 30, 2025, net income was $43.2 million, or $2.55 per diluted common share, compared to $33.2 million, or $1.96 per diluted common share for the same period in 2024, reflecting a 30.2% increase [114]. - Return on average equity (annualized) for Q3 2025 was 13.89%, compared to 10.36% in Q3 2024, indicating improved profitability [113]. - Return on average assets (annualized) for Q3 2025 was 1.47%, up from 1.05% in Q3 2024, showing enhanced asset efficiency [113]. Net Interest Income - Net interest income is the principal source of the Company's net income, driven by the difference between interest income and interest expense [115]. - The Company monitors yields on loans and interest-earning assets, costs of deposits, net interest spread, and net interest margin to evaluate net interest income [115]. - For the three months ended September 30, 2025, net interest income increased to $43.3 million, up 15.4% from $37.5 million in the same period of 2024 [122]. - Net interest income for the nine months ended September 30, 2025 was $124.0 million, an increase of $15.5 million, or 14.3%, compared to the same period in 2024 [124]. - The net interest margin for the three months ended September 30, 2025, was 4.05%, compared to 3.65% for the same period in 2024 [123]. - Net interest margin and net interest spread improved to 3.98% and 3.02%, respectively, for the nine months ended September 30, 2025, compared to 3.61% and 2.53% for the same period in 2024 [125]. Asset and Deposit Growth - Total assets of the company reached $4.41 billion as of September 30, 2025, compared to $4.26 billion in 2024 [122]. - Total deposits increased by $260.3 million, or 7.2%, to $3.88 billion at September 30, 2025, compared to $3.62 billion at December 31, 2024 [148]. - Noninterest-bearing demand deposits increased by $34.1 million for the three months ended September 30, 2025, compared to the same period in 2024 [122]. - Total average loans outstanding during the three months ended September 30, 2025, were $3,093.5 million, compared to $3,069.9 million for the same period in 2024 [174]. Credit Quality and Risk Management - The Company faces risks including economic growth rates, competition for deposits, and inflationary pressures that could impact future performance [107]. - The Company emphasizes the importance of maintaining effective internal controls and managing credit risk to safeguard financial results [112]. - The provision for credit losses for the nine months ended September 30, 2025 was $3.4 million, an increase of $300 thousand, or 9.7%, compared to $3.1 million for the same period in 2024 [128]. - The company continues to monitor credit quality due to ongoing economic uncertainties, including elevated interest rates and inflationary pressures [172]. - The allowance for credit losses (ACL) is evaluated quarterly, considering historical experience and current economic conditions [241]. Capital and Equity - As of September 30, 2025, total stockholders' equity increased to $477.8 million, up $38.9 million or 8.9% from $438.9 million as of December 31, 2024 [216]. - The Company is currently meeting all capital adequacy requirements and is classified as "well capitalized" under regulatory standards [218]. - Total capital to risk-weighted assets ratio was 17.34% as of September 30, 2025, compared to 17.86% as of December 31, 2024 [220]. - Tier 1 capital to risk-weighted assets ratio increased to 15.69% as of September 30, 2025, from 14.80% as of December 31, 2024 [220]. Interest Rate Risk Management - The ALCO Committee manages interest rate risk, considering factors such as earnings impact, regional economies, and liquidity [227]. - The company employs interest rate risk simulation models to assess the sensitivity of net interest income and fair value of equity [228]. - Under the static model, a 100 basis point shift in interest rates could lead to a maximum decline of 7.5% in estimated net interest income at risk for the subsequent one-year period [229]. - As of September 30, 2025, a 300 basis point increase in interest rates would result in a simulated decrease of 2.48% in net interest income [230].

Exhibit 99.1 Outlook Guidance for the fiscal year ending June 30, 2026 has been increased and now includes the Curtis acquisition: • Sales were a record $5.1 billion; organic sales growth was 5% • Net income was $808 million, an increase of 16%, or $927 million adjusted, an increase of 14% • EPS were $6.29, an increase of 18%, or a record $7.22 adjusted, an increase of 16% • Segment operating margin was 24.2%, an increase of 160 bps, or 27.4% adjusted, an increase of 170 bps • Cash flow from operations was ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission File Number: 001-39487 Silence Therapeutics plc (Exact name of registrant as specified in its charter) | England and Wales | ...

Viatris Reports Third Quarter 2025 Results and Updates 2025 Financial Guidance PITTSBURGH – November 6, 2025 – Viatris Inc. (Nasdaq: VTRS) today reported strong third quarter 2025 financial results and updated full-year financial guidance. Executive Commentary "We delivered another strong quarter by staying focused on our 2025 strategic priorities," said Scott A. Smith, Chief Executive Officer, Viatris. "Our performance this quarter reflects the continued strength of our execution across markets. We are adv ...